FDA authorizes updated Novavax COVID-19 vaccine

FDA authorizes updated Novavax COVID-19 vaccine

Washington – The United States Food and Drug Administration (FDA, in English) authorized this Tuesday the updated Novavax vaccine against COVID-19, which is designed to include protection against the omicron XBB.1.5 variant.

The FDA indicated in a statement that it authorizes the administration of this monovalent adjuvanted vaccine to people over 12 years of age.

Those who have already been vaccinated against the virus in the past will need one dose of the new Novavax vaccine, while those who have not yet received any will require two injections.

Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said the updated version of Novavax It is added to the arsenal of medications available against COVID-19 and recommended that the population get vaccinated for the fall.

The FDA also canceled the authorization to use the original monovalent Novavax vaccine as of Tuesday.

On September 11, it had approved the use of the updated Moderna and Pfizer/BioNTech vaccines, which use the messenger RNA technique, to combat variants such as omicron XBB.1.5.

The updated vaccines from Moderna and Pfizer/BioNTech are approved for those 12 years and older and authorized for emergency use for people 6 months to 11 years old.

Kumneger Media
Kumneger Media
Kumneger Media is a News and Entertainment Website & Channel. Kumneger Media in addition to News and Entertainment it is the hub of Politics, Movies, Drama, Music, Comedy, Documentary and More!